These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 26483331)
1. [Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation and Apoptosis of Lung Adenocarcinoma Cell H1975]. Zhang X; Liu G; Liu H; Ma T Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):599-609. PubMed ID: 26483331 [TBL] [Abstract][Full Text] [Related]
2. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. Zhang X; Liu G; Zhu X; Wang W Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):127-38. PubMed ID: 22429575 [TBL] [Abstract][Full Text] [Related]
3. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway. Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691 [TBL] [Abstract][Full Text] [Related]
4. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070 [TBL] [Abstract][Full Text] [Related]
5. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595 [TBL] [Abstract][Full Text] [Related]
6. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1]. Zhang W; Zhang W; Wang L; Zheng J; Xiao F Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641 [TBL] [Abstract][Full Text] [Related]
7. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. Wu M; Yuan Y; Pan YY; Zhang Y Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation. Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221 [TBL] [Abstract][Full Text] [Related]
10. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway. Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098 [TBL] [Abstract][Full Text] [Related]
11. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib]. Wang Q; Li M; Hu C Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882 [TBL] [Abstract][Full Text] [Related]
12. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795 [TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249 [TBL] [Abstract][Full Text] [Related]
14. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111 [TBL] [Abstract][Full Text] [Related]
16. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway. Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926 [TBL] [Abstract][Full Text] [Related]
17. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741 [TBL] [Abstract][Full Text] [Related]
18. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738 [TBL] [Abstract][Full Text] [Related]
19. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Wang Z; Tang F; Hu P; Wang Y; Gong J; Sun S; Xie C Oncol Rep; 2016 Jul; 36(1):589-97. PubMed ID: 27221381 [TBL] [Abstract][Full Text] [Related]
20. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations. Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]